December 25, 2014 7:43 AM ET

Biotechnology

Company Overview of Gliknik, Inc.

Company Overview

Gliknik, Inc., a biopharmaceuticals company, develops therapies for patients with cancer and autoimmune/inflammatory disorders. It offers immunomodulators, which are peptide drugs that increase CD4, CD8, and antibody immune responses against targeted cancer epitopes with the goal of turning a cancer patient’s immune system against his or her tumor. The company also provides Stradomers, which are recombinant drugs for a range of inflammatory and autoimmune diseases; Stradomer-coated device platform, a drug coating to prevent the body's normal reaction to implanted devices; and Stradobody Platform, which provides biologics similar to monoclonal antibodies with increased tumor cell killing. Gli...

801 West Baltimore Street

Suite 501A

Baltimore, MD 21201

United States

Founded in 2007

Phone:

410-685-4258

Key Executives for Gliknik, Inc.

Founder
Age: 54
Founding Scientist
Board Observer
Vice President of Drug Discovery
Senior Director of Clinical Development
Compensation as of Fiscal Year 2014.

Gliknik, Inc. Key Developments

Gliknik, Inc. Announces New Appointment

Gliknik, Inc. announced that it has expanded its team by adding a new Senior Director of Clinical Development and electing two new members to its Board of Directors. Jeffrey Herpst, R.N., joins Gliknik as Senior Director, Clinical Development. Mr. Herpst has 20 years' experience in clinical operations and has held clinical development roles of increasing responsibility, most recently at Zyngenia, Teva, and Human Genome Sciences. Richard Levy, M.D., has been elected to the Gliknik Board of Directors to further enhance the company's clinical resources. Dr. Levy currently is EVP, Chief Drug Development and Medical Officer at Incyte Corporation. Mark Lerner has also been elected to the Gliknik Board of Directors. Mr. Lerner is a co-founding Partner of Chesapeake Partners.

Gliknik, Inc. Signs Licensing Agreement with Pfizer Inc

Gliknik, Inc. has entered into an exclusive worldwide licensing agreement with Pfizer, Inc. for GL-2045, Gliknik's recombinant stradomer(TM), a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). Both the companies are based in the US. Under the terms of the agreement, Pfizer will receive an exclusive worldwide license to GL-2045 for all therapeutic indications. Gliknik will receive an upfront payment of $25 million and is eligible to receive development, regulatory and commercial milestone payments. Gliknik is also eligible to receive tiered, double-digit royalties on net sales of any products that are commercialized pursuant to the license agreement.

Gliknik, Inc. Enters into Licensing Agreement with Pfizer Inc. for Drug Candidate Targeting Autoimmune Diseases

Gliknik Inc. announced that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. for GL-2045, Gliknik's recombinant stradomer(TM), a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising results in a broad range of preclinical tests and is being developed as a potential treatment for a wide variety of autoimmune diseases, including those in which IVIG is clinically used. Under the terms of the license agreement, Pfizer will receive an exclusive worldwide license to GL-2045 for all therapeutic indications. Gliknik will receive an upfront payment of $25 million and is eligible to receive development, regulatory and commercial milestone payments. Gliknik is also eligible to receive tiered, double-digit royalties on net sales of any products that are commercialized pursuant to this license agreement. GL-2045 is Gliknik's lead preclinical recombinant stradomer(TM) for autoimmune diseases. It has demonstrated potent efficacy in numerous preclinical tests and is in IND-enabling manufacturing. GL-2045 acts by presenting highly ordered multimers of normal human IgG Fc to its receptors.

Similar Private Companies By Industry

Company Name Region
Biotech Research, Inc. United States
Kibow Biotech, Inc. United States
CellExSys, Inc. United States
Sutro Biopharma, Inc. United States
CeraPedics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Gliknik, Inc., please visit www.gliknik.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.